Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masashi Nomi has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of the 3‐Year Continuation Rate and Discontinuation Factors Between Vibegron and Mirabegron in Patients With Overactive Bladder: A Retrospective Follow‐Up Study in a Rehabilitation Hospital in Japan

    by Shigeto Mukai, Masashi Nomi, Akihiro Yanagiuchi, Atsushi Sengoku

    Objectives: The objective of this study is to compare the 3‐year continuation rate and discontinuation factors between vibegron and mirabegron in patients with overactive bladder in a rehabilitation hospital in Japan.Methods: The 3‐year continuation rate of the target drugs and reasons for discontinuation as well as patients' backgrounds and adverse effects were evaluated retrospectively from the medical records between September 2018 and December 2020. After selecting patients according to our inclusion and exclusion criteria, 136 cases taking mirabegron and 82 taking vibegron were adjusted for intergroup variability by propensity score matching. We performed Cox proportional hazards regression for the 3‐year continuation rate and Fine‐Gray proportional hazards regression for the 3‐year cumulative incidence of discontinuation events. Subgroup analysis was also performed.Results: Approximately 70% of the patients analyzed had neurogenic overactive bladder. The 3‐year continuation rate was 65.2% in vibegron and 30.3% in mirabegron, and the hazard ratio was 0.41 (95% confidence interval: 0.25–0.68, p < 0.001) as for an incidence of discontinuation events of vibegron against mirabegron. The incidence of discontinuation due to inadequate efficacy was 22.7% in vibegron and 47.0% in mirabegron, and similarly the hazard ratio was 0.43 (95% confidence interval: 0.23–0.80, p < 0.01). In the subgroup analysis, vibegron continued significantly more than mirabegron for the 3‐year continuation rate in non‐neurogenic overactive bladder (p < 0.001), in spontaneous voiding (p < 0.001), in anticholinergic combination (p = 0.0017), in female (p < 0.001), and in 70 years or older (p = 0.0028). Additionally, a significant interaction was observed regarding the methods of emptying urine (p = 0.0066).Conclusions: Vibegron was superior to mirabegron in the 3‐year continuation rate of administration with a fewer discontinuation due to inadequate efficacy in a patient population with relatively high rates of neurogenic overactive bladder.


  • Open Access

    Pathophysiology and Evaluation of Voiding and Defecation

    by Masashi Nomi, Atsushi Sengoku

    排尿を司る膀胱・尿道(下部尿路)と排便を司る大腸・肛門は,ともに中枢神経と末梢神経系の制御を受けている.そして,その神経障害のレベルにより,前者は橋上型,核上型・橋下型,および核・核下型の神経因性下部尿路障害(神経因性膀胱),後者は反射性大腸および弛緩性大腸のタイプの神経因性大腸機能障害を呈することになる. 排尿障害と排便障害は,それぞれ大きく排尿障害(尿排出障害)と蓄尿障害,および便秘と便失禁とに分けられるが,その原因は神経因性の機能障害に限らず,ADL障害も含めて多岐にわたり,また症例ごとに種々の程度に複合している.従って,その評価においては症例ごとに全身的な検索が必要となる.

  • Hygiene management of intermittent self‐catheterization using reusable silicone catheters in people with spinal cord lesions: A cross‐sectional Internet survey in Japan

    by Ryosuke Takahashi, Noritoshi Sekido, Mihoko Matsuoka, Atsushi Sengoku, Masashi Nomi, Fujio Matsuyama, Tatsunori Murata, Takeya Kitta, Takahiko Mitsui

    Objectives: To investigate hygiene management and catheter maintenance of reusable silicone catheters for intermittent self‐catheterization (ISC) in Japan and examine their relationship with symptomatic urinary tract infection (sUTI).Methods: We conducted a cross‐sectional Internet survey of people performing ISC using reusable silicone catheters owing to spinal cord lesions in Japan. Hygiene management and catheter maintenance of reusable silicone catheters and the incidence and frequency of sUTI were evaluated. We also examined the significant risk factors for sUTI.Results: Of 136 respondents, 62 (46%), 41 (30%), and 58 (43%) washed hands with water, washed hands with soap, and cleaned or disinfected the urethral meatus every time or most of the time before ISC, respectively. No significant difference was observed in the incidence and frequency of sUTI between respondents who adhered to these procedures and those who did not. There were no significant differences in the incidence and frequency of sUTI in respondents who changed their catheters every month and in those who changed their preservation solution within 2 days compared with those who did not. In multivariate analysis, pain during ISC, inconvenience of indoor mobility, bowel management problems, and participants' feeling of never having received instruction on catheter replacement were significant risk factors for sUTI.Conclusions: There are individual differences in hygiene management and catheter maintenance of reusable silicone catheters, but the influence of these differences on the incidence and frequency of sUTI is not clear. Pain during ISC, bowel management problems, and inadequate instruction on catheter maintenance procedures are factors associated with sUTI.


  • The impact of the coronavirus disease 2019 pandemic on changes in antimicrobial prophylaxis and development of genito‐urinary tract infections after urodynamic study: A retrospective comparative study of a single rehabilitation hospital in Japan

    by Shigeto Mukai, Masashi Nomi, Sae Kozawa, Akihiro Yanagiuchi, Katsumi Shigemura, Atsushi Sengoku

    Aims: To investigate the changes in the proportion of antimicrobial prophylaxis (AP) during the urodynamic study (UDS) and the frequency of posttest genito‐urinary tract infections (GUTI) before and after coronavirus disease 2019 (COVID‐19) pandemic, and evaluate this associations.Patients and Methods: Patients who underwent UDS between 2015 and 2021 were targeted, and they were allocated to pre‐2020 as before the appearance of COVID‐19 and post‐2020 as after that, and propensity score matching was performed. The impact on AP was assessed by the administration rate, and that on the development of febrile GUTI after UDS was assessed for an equivalence by the GUTI‐free rate at 7 days after testing.Results: After matching, 384 cases of 192 cases each were included. The frequency of AP was 58.3% in pre‐2020 and 77.1% in post‐2020, an increase of about 19%, and the rate increased significantly in post‐2020 (p < 0.001). However, the incidence of GUTI after UDS was 4.2% and 4.7%, respectively, with no significant difference. The ratio of GUTI‐free rates was within the equivalence margin, confirming an equivalence before and after the appearance of COVID‐19.Conclusions: Under the influence of COVID‐19 pandemic, even though AP rate during UDS was increased by 19% from that brought by following the guideline‐based administration methods, the frequency of GUTI after UDS was similar, so it is thought to be important to use AP during UDS appropriately for high‐risk cases as recommended in the guidelines.


  • Retrospective Observational Study of Risk Factors for Febrile Infectious Complications after Urodynamic Studies in Patients with Suspected Neurogenic Lower Urinary Tract Disturbance

    by Nozomi Takami, Shigeto Mukai, Masashi Nomi, Akihiro Yanagiuchi, Atsushi Sengoku, Koki Maeda, Young-Min Yang, Katsumi Shigemura, Masato Fujisawa

    Introduction: We retrospectively investigated the risk factors for post-urodynamic study (UDS) infectious complications in long-term hospitalized inpatients with suspected neurogenic lower urinary tract disturbance (NLUTD) in a monocenter study, to accurately assess post-UDS urinary tract infections (UTI). Methods: We retrospectively analyzed data including background information, UDS-related data, and potential risk factors for infection from 489 NLUTD-suspected inpatients who underwent UDS from 2015 to 2019 and examined the risk factors for post-UDS infectious complications using univariate and multivariate statistical analyses. Results: Symptomatic post-UDS UTI occurred in 20 out of 489 (4.1%) patients, including 3 (15%) with recurrent UTI. During follow-up prior to UDS for 1 year, 220 cases were investigated by urine culture revealing Escherichia coli (n = 77), Klebsiella pneumoniae (n = 29), Enterococcus faecalis (n = 18), extended-spectrum beta-lactamase-producing E. coli (n = 17), and Pseudomonas aeruginosa (n = 9). As risk factors for post-UDS infectious complications, American Spinal Injury Association impairment scale (AIS): AIS ≧ C (A or B or C) (hazard ratio: 4.29, p = 0.0076), management method of urination (hazard ratio: 4.30, p = 0.048), and age (hazard ratio: 1.04, p = 0.025) were significantly correlated with the occurrence of post-UDS infection. Conclusions: The significant risk factors for post-UDS UTI were AIS ≧ C, management method of urination, and age in the suspected NLUTD patient context. This study was originally started with the goal of reducing unnecessary antibiotics and may contribute to the proper use of antibiotics based on antimicrobial stewardship.


  • Open Access

    Validation of the Monitoring Efficacy of Neurogenic Bowel Treatment on Response (MENTOR) Tool in a Japanese Rehabilitation Setting

    by Masashi Nomi, Atsushi Sengoku, Klaus Krogh, Anton Emmanuel, Albert Bohn Christiansen

    Study design: Prospective observational study. Objective: To validate the Monitoring Efficacy of NBD Treatment On Response (MENTOR) tool in individuals with a spinal cord injury (SCI) or spina bifida, suffering from neurogenic bowel dysfunction (NBD) in a rehabilitation center in Japan. Methods: First, the MENTOR tool was translated from English to Japanese using a validated translation process. Second, the MENTOR tool was validated in a rehabilitation clinic in Japan. Participants completed the MENTOR tool prior to a consultation with an expert physician. According to the results of the tool, each participant was allocated to one of three categories regarding change in treatment: “adequately treated,” “further discussion,” and “recommended change.” The results of the MENTOR tool were compared with the treatment decision made by an expert physician, who was blinded to the results of the MENTOR tool. Results: A total of 60 participants completed the MENTOR tool. There was an acceptable concordance between individuals allocated as respectively, being adequately treated (100%) and recommended change in treatment (61%) and the physicians’ decision on treatment. The concordance was lower for individuals allocated as requiring further discussion (48%). Conclusions: In this study the MENTOR tool was successfully validated in a Japanese rehab setting. The tool will help identify individuals with SCI that need further treatment of their NBD symptoms.


  • Risk factors for febrile genito-urinary infection in the catheterized patients by with spinal cord injury-associated chronic neurogenic lower urinary tract dysfunction evaluated by urodynamic study and cystography: a retrospective study

    by Katsumi Shigemura, Koichi Kitagawa, Masashi Nomi, Akihiro Yanagiuchi, Atsushi Sengoku, Masato Fujisawa

    To investigate the risk factors for febrile genito-urinary tract infection (GUTI) in spinal cord injury-associated neurogenic lower urinary tract dysfunction (NLUTD) patients who perform routine clean intermittent catheterization (CIC) evaluated by urodynamic study (UDS) and cystography.


  • Open Access

    Value of prostate specific antigen alpha1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0ng/mL: Comparison with PSA-related parameters

    by Hideaki Miyake, Shoji Hara, Masashi Nomi, Soichi Arakawa, Sadao Kamidono, Isao Hara

    Background: The aim of the present study was to evaluate the usefulness of prostate specific antigen α1‐antichymotrypsin complex (PSA‐ACT) in the differential diagnosis of prostate cancer in patients with a PSA level of 4.1–10.0 ng/mL compared to several PSA‐ and PSA‐ACT‐related parameters. Methods: Serum samples were obtained from 103 patients with no evidence of malignancy on biopsy and 29 with histologically confirmed prostate cancer. All patients had pretreatment serum PSA levels between 4.0 and 10.0 ng/mL. The different forms of serum PSA, including total PSA (tPSA), free PSA (fPSA) and PSA‐ACT were measured using immunofluorometric techniques with different monoclonal antibodies against PSA and ACT. Furthermore, tPSA and PSA‐ACT densities of the whole prostate (PSAD and ACTD, respectively) and the f‐to‐tPSA and the f‐to‐PSA‐ACT ratios (F/T ratio and F/ACT ratio, respectively) were calculated. Results: The differences between patients with prostate cancer and benign prostatic disease were significant with respect to all six parameters examined in this study. Analysis of receiver operating characteristics revealed that the areas under the curve for PSA‐ACT, ACTD and the F/ACT ratio were larger than those for tPSA, PSAD and the F/T ratio, respectively. However, there were no significant differences in discrimination between benign and malignant diseases among these six parameters. Conclusions: In patients who have an intermediate serum PSA level, PSA‐ACT and its associated parameters may not be significantly superior in the differential diagnosis between prostate cancer and benign prostatic diseases compared to tPSA and its traditional relatives.